XY018 is a Potent RORγ Selective Antagonist
Persistent or reactivated signaling by the androgen receptor drives the progression of prostate cancer to a deadly form of the disease, namely metastatic castration-resistant prostate cancer (mCRPC). The RAR-related orphan…